8-K: Talphera Secures $17M, Extends Cash Runway Through Niyad PMA

Talphera, Inc. announced third quarter 2025 financial results, including a $17 million financing tranche and an extended cash runway through potential Niyad PMA approval in late 2026, alongside progress in its NEPHRO study.

Summary

• Closed the first tranche of a $17 million private placement financing in September 2025, led by CorMedix, Inc., as part of a larger financing up to $29 million.
• Cash and investments balance was $21.3 million as of September 30, 2025, which, combined with conditional future tranches, is expected to provide sufficient capital through a potential PMA approval of Niyad in late 2026.
• Five of the nine target profile clinical sites for the NEPHRO study are now activated, with four additional sites expected in the fourth quarter of 2025.
• Completion of the NEPHRO study is expected in the first half of 2026.
• Net loss from continuing operations for the third quarter of 2025 was $4.4 million, compared to $3.4 million for the third quarter of 2024, largely due to an increase in the fair value of the warrant liability.
• Net loss attributable to common shareholders for Q3 2025 was $4.4 million, or $0.11 per basic and diluted share, compared to $3.4 million, or $0.13 per basic and diluted share, for Q3 2024.
• Combined Research & Development (R&D) and Selling, General & Administrative (SG&A) expenses for Q3 2025 totaled $3.4 million, a decrease from $3.7 million for Q3 2024.
• The 2025 cash operating expense guidance has been reduced to a range of $14 million to $15 million, down from the previously provided $16 million to $17 million range.
• Joseph Todisco, CEO of CorMedix, was appointed to Talphera's board of directors in October 2025, following CorMedix's strategic investment.

Sentiment

Score: 7

Explanation: The filing presents a positive outlook driven by successful financing, extended cash runway, and significant progress in the pivotal NEPHRO study. While net loss increased, it was primarily due to a non-operating warrant liability adjustment, and operating expenses were reduced. The strategic partnership with CorMedix further validates the company's direction.

Positives

• Secured $17 million in the first tranche of a private placement financing, significantly bolstering capital.
• Extended cash runway to late 2026, providing sufficient capital through potential Niyad PMA approval.
• Strategic investment from CorMedix, Inc. validates the attractiveness of the Niyad market opportunity.
• Significant progress in the NEPHRO study with 5 of 9 target clinical sites actively enrolling patients and positive enrollment momentum.
• Reduced combined R&D and SG&A expenses to $3.4 million in Q3 2025 from $3.7 million in Q3 2024.
• Reduced 2025 cash operating expense guidance to $14 million-$15 million from $16 million-$17 million.
• Appointment of Joseph Todisco, CEO of CorMedix, to the board of directors, enhancing strategic alignment.
• Niyad has received Breakthrough Device Designation status from the U.S. Food and Drug Administration (FDA).

Negatives

• Net loss from continuing operations increased to $4.4 million in Q3 2025 from $3.4 million in Q3 2024.
• The increase in net loss was largely due to an increase in the fair value of the Company's warrant liability.

Risks

• Clinical studies may not be fully enrolled or completed as anticipated.
• Clinical studies may not confirm any safety, efficacy, or other potential developmental product characteristics described or assumed.
• Developmental product candidates may not be beneficial to patients or healthcare providers or be successfully commercialized.
• Inability to obtain regulatory approvals for developmental product candidates.
• Risks related to the ability of Talphera and its business partners to implement development plans, commercial launch plans, forecasts, and other business expectations.
• Risks related to liquidity and the ability to maintain capital resources sufficient to conduct clinical studies.

Future Outlook

Talphera expects to complete the NEPHRO CRRT study in the first half of 2026 and anticipates potential PMA approval for Niyad in late 2026. The company plans to activate four additional target clinical sites in the fourth quarter of 2025 and projects its current cash, combined with conditional future financings, will be sufficient through Niyad's potential PMA approval. Cash operating expenses for 2025 are guided to be in the range of $14 million to $15 million, a reduction from previous estimates.

Management Comments

• "The financing closed in September, led by a strategic investment from CorMedix, combined with future conditional tranches, is expected to provide us sufficient capital through at least a Niyad PMA approval anticipated in 2026." Vince Angotti, CEO
• "Their investment, along with investment from existing and new financial investors, further validates the attractiveness of the Niyad market opportunity." Vince Angotti, CEO
• "We're excited about the high quality and skilled execution of the NEPHRO study sites. Importantly, we have received consistent feedback from the principal investigators conveying eagerness for nafamostat to be available as their preferred alternative to current CRRT anticoagulants." Vince Angotti, CEO
• "The positive enrollment momentum in the NEPHRO clinical study has continued and we look forward to the recently activated sites and the remaining four planned sites to further accelerate the enrollment rate to complete the study in the first half of 2026." Vince Angotti, CEO

Industry Context

Talphera operates in the specialty pharmaceutical sector, focusing on developing innovative therapies for medically supervised settings. Its lead product candidate, Niyad (nafamostat), addresses a critical unmet need for anticoagulation in extracorporeal circuits, particularly for patients undergoing Continuous Renal Replacement Therapy (CRRT) who cannot tolerate heparin or are at high risk for bleeding. The Breakthrough Device Designation from the FDA underscores the significant potential for Niyad to offer a superior alternative to existing CRRT anticoagulants, positioning Talphera to potentially capture a substantial share of this niche market.

Management Changes

Corporate Governance

Related Party Transactions

• CorMedix, Inc. led the $17 million first tranche of a private placement financing.
• Talphera granted CorMedix the right to nominate one member to its board of directors.
• Talphera granted CorMedix the exclusive right of first negotiation for a potential acquisition of the Company.
• Joseph Todisco, CEO of CorMedix, was appointed to Talphera's board of directors.

Stakeholder Impact

• Shareholders: Potential for increased value due to extended cash runway, clinical progress, and strategic partnership. However, the right of first negotiation for CorMedix could impact future acquisition premiums. Dilution from the capital raise is also a factor.
• Employees: Continued operations and progress on the lead product candidate, Niyad, provide stability and future prospects.
• Customers (healthcare providers/patients): Potential for a new, preferred anticoagulant (Niyad) for CRRT patients who cannot tolerate existing therapies.
• Creditors: Improved financial stability and liquidity due to the capital raise.

Next Steps

• Activate four additional target profile clinical sites for the NEPHRO study in the fourth quarter of 2025.
• Accelerate the enrollment rate in the NEPHRO study with recently activated and planned sites.
• Complete the NEPHRO study in the first half of 2026.
• Pursue potential PMA approval of Niyad in late 2026.
• Hold a conference call and webcast on November 12, 2025, at 4:30 p.m. ET to discuss results and provide a business update.

Key Dates

Recommendation

The filing presents a mixed but generally positive picture. The successful financing and extended cash runway are critical for continued operations and Niyad's development. Progress in the NEPHRO study and reduced operating expense guidance are also favorable. However, the company remains pre-revenue with an increased net loss, albeit due to a non-operating item. The strategic partnership with CorMedix offers validation and a potential future exit but also introduces a right of first negotiation that could limit competitive bidding. Investors should hold to monitor the NEPHRO study results and further progress towards Niyad's PMA approval, as these milestones will be key determinants of future value.

Keywords

Talphera, TLPH, Niyad, nafamostat, NEPHRO study, CRRT, anticoagulant, specialty pharmaceutical, FDA Breakthrough Device, CorMedix, private placement, financial results, Q3 2025, clinical trial, corporate update